北京大学肿瘤医院于2005年成立了中药药理 (肿瘤) 实验室，致力于中药抗肿瘤作用及机制的研究，为中西医结合治疗肿瘤，提高患者生存质量做出努力。2009年该实验室通过评审被认证为国家中医药管理局“中医药科研三级实验室”，以中医药管理局的科研实验室分级管理为契机，全面推动实验室的建设和发展。自2010年起，医学部连续两年对该平台进行了资助，进一步提升了该平台的硬件条件，为科研工作的开展提供了良好的支撑作用。

研究领域及方向

    1. 肿瘤生长和转移微环境及中药的调节作用及机制

    2. 肿瘤微环境及中药的调节作用及机制

    3. 中药对肿瘤代谢的影响

   

    本研究室的学科水平不断提高，在抗肿瘤中药药理研究领域的影响力不断增强。自认证后，本平台共获得国家级、省部级和厅局级等课题近40项，参加了北京市科委的科技计划重大项目、国家科技支撑计划课题、“重大新药创制”科技重大专项等课题的研究。并与美国DUKE大学、加拿大卫生研究院、澳大利亚的西悉尼大学等联合开展了在肿瘤症状评估领域的国际合作。在学科领域内的TOP杂志发表了相关研究结果，并多次被引用。

    研究室主任李萍萍教授在肿瘤中西医结合领域具有很高的学术地位和影响力。针对肿瘤患者缺乏客观评价中医症状标准的问题，建立了国际公认的中医肿瘤症状改善的客观评价方法。国内首家开展了针对老年肿瘤患者的综合评估CGA (Comprehensive Geriatric Assessment)，制定了切实可行且较好信度、效度及内在一致性的《老年肿瘤患者综合评估量表》。

    课题组的系列研究成果先后荣获2011年华夏科技奖三等奖、2012年教育部科学技术进步二等奖和2019年中西医结合学会科技奖三等奖。研究结果在知名的学术会议如全国中西医结合肿瘤学术大会、CSCO、日本JCA年会、美国AACR年会进行交流并多次获奖，充分展示了学科建设的成效，不断扩大本室在国内外的影响力。

近年来的重要科研成果及贡献

    1. 系统研究了通关藤提取物改善非小细胞肺癌酪氨酸激酶抑制剂耐药的作用，并从信号调控、药物代谢、细胞自噬及肿瘤微环境等途径探讨了其作用机理，为中药改善分子靶向药耐药提供了科学依据。

    2. 研究了加味补肺方抑制肿瘤生长和肺转移，延长小鼠生存时间的作用，并从免疫调控、肿瘤-血管相互作用角度阐明了其机制。为经典方药的临床应用提供了科学支撑，并丰富其内涵。

    3. 疲乏是癌症患者最常见症状，中医辨证多为气血两虚。利用随机对照临床研究证明，复方人参养荣汤可以有效改善化疗患者和癌症生存者的疲乏症状及整体生活质量，为该方的应用提供了科学依据。

    4.深入研究了蒲公英提取物多途径抑制三阴性乳腺癌进展的作用机制。并首次揭示了CUEDC2分子促进三阴乳腺癌的作用及新机制。

机构负责人：李萍萍

联系人：韩淑燕

邮箱：shuyanhan@bjmu.edu.cn

电话：010-88196273

地址：北京市海淀区阜成路52号

Third-level Laboratory of Anti-tumor Pharmacology of TCM

accredited by the National Administration of Traditional Chinese Medicine

Peking University Cancer Hospital established the Traditional Chinese Medicine Pharmacology (Tumor) Laboratory in 2005, which aims to study the anti-tumor effects and mechanisms of herbal medicine, and making efforts to treat tumors with integrated Chinese and Western medicine and improve the quality of life of patients. In 2009, the laboratory was accredited as the "Third-level Laboratory of Traditional Chinese Medicine Research" by the National Administration of Traditional Chinese Medicine.

Taking the opportunity of the hierarchical management of scientific research laboratories offered by the National Administration of Traditional Chinese Medicine, it promotes the construction and development of our laboratory in an all-round way. Since 2010, the Peking University Health Science Center has funded the platform for two consecutive years, which further improved the equipment condition of the platform and provided a good support for the scientific research.

Research field and direction

1. Tumor growth and metastasis microenvironment and the regulatory effect and mechanism of Chinese medicine.

2. Tumor microenvironment and the regulatory effect of Chinese medicine.

3. The influence on tumor metabolism by Chinese medicine.

The subject level and academic influence of our laboratory are constantly improving in the field of anti-tumor pharmacology of traditional Chinese medicine. Our laboratory has obtained nearly 40 projects funding provided by NSFC, Beijing Municipal Science and Technology Commission and Beijing Administration of Traditional Chinese Medicine, etc. We also participated in the major scientific and technological projects of the Beijing Municipal Science and Technology Commission, the national scientific and technological support project, and the major scientific and technological special project of "Major New Drug Creation". Our group has carried out international cooperation with DUKE University in the United States, the Canadian Institutes of Health Research, and Western Sydney University in Australia in the field of tumor symptom assessment. Related research results have been published in the TOP journals in the subject area and have been cited frequently.

Professor Li Pingping, the director of our lab, has a high academic status and influence in the field of integrated Chinese and Western medicine. In view of the lack of objective evaluation criteria for TCM symptoms in tumor patients, Prof. Li led the establishment of an internationally recognized objective evaluation method for TCM tumor symptom. Prof. Li also directed a research on Comprehensive Geriatric Assessment (CGA) for elderly cancer patients in our country for the first time, and established a practical and reliable "Comprehensive Geriatric Assessment Scale for Elderly Cancer Patients".

Our research results of successively won the third prize of Huaxia science and Technology Award in 2011, the second prize of Science and Technology Awards by China’s Ministry of Education in 2012, and the third prize of Science and Technology Award by Society of Integrative Medicine in 2019. Our research results were presented and won paper award at well-known academic conferences such as the National Conference on Integrated Chinese and Western Medicine Oncology, CSCO, Annual meeting of the Japanese Cancer Association, and Annual meeting of American Association for Cancer Research. These activities fully demonstrate the effectiveness of discipline construction and increasing the influence of our lab both domestic and abroad. We have published 10 papers in the SCI-indexed journals with a total impact factors of 45.5.

Important scientific research achievements

1. We found Marsdenia Tenacissima extract could restore the sensitivity of tyrosine kinase inhibitors (TKI) in the resistant non-small cell lung cancer (NSCLC), and its effects have been achieved by regulating drug resistance-related signaling pathways, drug metabolism, autophagy and tumor microenvironment. This study provides a scientific evidence and potential way for improving TKI efficacy in NSCLC by Chinese medicine.

2. Modified Bufei Decoction is derived from the Bufei Decoction in the Yuan Dynasty, and improve the symptoms of lung qi deficiency in lung cancer patients. We found Modified Bufei Decoction could inhibit tumor growth and metastasis in vitro and in vivo, improve the immune ability of mice by enhancing immune response and decreasing immunosuppression, and Modified Bufei Decoction functions better than the original recipe. These results offer scientific support for the clinical application of classic prescriptions and enrich their scientific connotation.

3. Fatigue is the most common symptom in cancer patients, and the deficiency of Qi and blood is the highest incidence among cancer-related fatigue. Randomized controlled clinical studies have proved that compound ginseng Yangrong Decoction can effectively improve the fatigue symptoms and the overall quality of life in patients receiving chemotherapy or cancer survivors, providing a scientific basis for the application of the prescription.

4. We intensely studied the effects and mechanisms of Dandelion extract on inhibiting triple-negative breast cancer (TNBC). For the first time, we reported an important effect of CUEDC2 in accelerating TNBC progression. More importantly, we identified a novel mechanism by which CUEDC2 promotes TNBC development.

Director: Pingping Li

Contact: Shuyan Han

Email: shuyanhan@bjmu.edu.cn

TEL: 010-88196273

Address: No 52 Fucheng Road, Haidian District, Beijing 100142